tiprankstipranks
Trending News
More News >
TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market

TScan Therapeutics (TCRX) Income Statement

Compare
312 Followers

TScan Therapeutics Income Statement

Last quarter (Q3 2025), TScan Therapeutics's total revenue was $2.51M, an increase of 277.59% from the same quarter last year. In Q3, TScan Therapeutics's net income was $-35.71M. See TScan Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 2.82M$ 21.05M$ 13.54M$ 10.14M$ 1.08M
Gross Profit
$ 2.82M$ 21.05M$ 13.54M$ 10.14M$ -19.49M
Operating Expenses
$ 137.64M$ 114.51M$ 80.17M$ 58.78M$ 6.74M
Depreciation and Amortization
$ 4.11M$ 5.36M$ 5.14M$ 3.33M$ 1.23M
EBITDA
$ -119.74M$ -80.10M$ -59.91M$ -45.30M$ -25.00M
Operating Income
$ -134.82M$ -93.46M$ -66.64M$ -48.64M$ -26.23M
Other Income/Expenses
$ 7.32M$ 4.24M$ 415.00K$ 16.00K$ 106.00K
Pretax Income
$ -127.50M$ -89.22M$ -66.22M$ -48.63M$ -26.13M
Net Income
$ -127.50M$ -89.22M$ -66.22M$ -48.63M$ -26.13M
Per Share Metrics
Basic EPS
$ -1.14$ -1.36$ -2.74$ -2.03$ -1.04
Diluted EPS
$ -1.14$ -1.36$ -2.74$ -2.03$ -1.04
Weighted Average Shares Outstanding
111.99M 65.60M 24.05M 23.91M 24.94M
Weighted Average Shares Outstanding (Diluted)
111.99M 65.60M 24.05M 23.91M 24.94M
Currency in USD

TScan Therapeutics Earnings and Revenue History